POPULARITY
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Ann H. Klopp to discuss radiation alone vs chemoradiation in endometrial cancer recurrence. Dr. Ann H. Klopp is a Professor of Radiation Oncology at MD Anderson Cancer Center, the head of the Gynecologic Oncology Section and a physician-scientist specializing in the treatment of gynecologic cancers. Her research focuses on improving outcomes for women with gynecologic cancers by enhancing tumor directed immune response in combination with radiation therapy and using advanced techniques to increase precision of radiation treatment delivery. Highlights: NRG0238 compared chemoradiation to radiation alone for patients with locally recurrent endometrial cancer and found that the addition of chemotherapy did not improve progression-free survival. Radiation therapy is highly effective for treatment for local recurrences of endometrial cancer. The nuances of patients enrolled and treatment delivered are discussed.
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Domenica Lorusso to discuss the KEYNOTE A18 clinical trial. Dr. Domenica Lorusso, MD, PhD, directs the Gynaecological Oncology Unit at Humanitas Hospital, Milan, and holds a Full Professorship in Obstetrics and Gynaecology at Humanitas University, Rozzano, Milan. She has led/participated in approximately 250 phase I-IV clinical trials. Currently overseeing more than 60 studies as Principal Investigator, Dr. Lorusso also chairs the Clinical Trials Committee of the MITO Group. She serves on the Board of Directors of the GCIG and is an active member of ENGOT, where she chairs the Gynecological Cancer Academy. Additionally, she sits on the Board of Directors of the ESGO. With around 300 international oncology publications and contributions to national and international treatment guidelines, her primary objectives are to ensure optimal patient care, foster clinical research, and advance international collaborations and education in the field. Highlights: - Concurrent chemoradiation plus brachiterapy represent the standard of care treatment in locally advanced cervical cancer providing up to 70% 5 years OS - Modern radiotherapy technique (IMRT and VMAT) has reported to further increase OS and reduce toxicity - Immunotherapy has reported to increase OS in advanced or recurrent cervical cancer when compared to standard treatment - Immunotherapy in combination with concurrent high quality chemoradiation in the treatment of locally advanced high risk cervical cancer further increase PFS and OS with respect to standard chemoradiotherapy and should be considered the new standard of care - The combination appears manageable and no substanciad additional toxicity has been reported
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Professor Gemma Kenter to discuss EORTC 55994. Prof. Kener is emeritus professor in gynae-oncology and was head of the department gynae-oncology in Center of Gynaecological Oncology Amsterdam (Amsterdam University Medical Center and Dutch Cancer Center). Her scientific interest concerns treatment and translational research of carcinoma of the cervix. Highlights: In Trial EORTC 55994 we found no difference in overall survival between neoadjuvant chemotherapy followed by radical surgery and concomitant chemoradiation in case of bulky cervical cancer. Regions in the world with a high incidence of cancer of the cervix might have poor access to radiotherapy. For patients in these centers as well as for young women who want to perceive their ovarian function, neoadjuvant chemotherapy followed by radical surgery can be a good alternative.
In de podcastserie proefschriften spreekt AIOS Interne geneeskunde dr. Tessa Steenbruggen met promovendi. In deze aflevering spreekt zij met onderzoeker Lisa van Hoogstraten over haar proefschrift, getiteld “Bladder cancer care in the Netherlands | Guidelines and practice: are they in harmony?”. Aan bod komen de resultaten verkregen uit verschillende studies binnen het BlaZiB, Blaaskankerzorg In Beeld, naar de behandeling van blaaskanker in Nederland. Lisa zal op 19 december a.s. haar proefschrift verdedigen aan de Radboud Universiteit Nijmegen.Referenties Mukherjee S. (2011). The emperor of all maladies - Siddhartha Mukherjee. Simon & Schuster. BlaZiB: Insight into bladder cancer care: study protocol of a large nationwide prospective cohort study (BlaZIB) | BMC Cancer | Full Text (biomedcentral.com) Neoadjuvante behandeling blaaskanker: Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer | World Journal of Urology (springer.com) Blaassparende behandelingen: Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: A nationwide cohort study - ClinicalKey
Oncologist Yee Pei Song and editor Mike Leveridge talk about bladder cancer, and how chemoradiotherapy can help preserve the bladder.
Dr Katz discusses the implications of a recently published phase 2 study investigating neoadjuvant mFOLFIRINOX with or without hypofractionated radiation therapy results for patients with borderline resectable pancreatic ductal adenocarcinoma.
A new research paper was published in Oncotarget on July 28, 2022, entitled, “Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer.” DNA damage and resulting neoantigen formation is considered a mechanism for synergy between radiotherapy and PD-1/PD-L1 pathway inhibition to induce antitumor immune response. In a new research study, by Marina Baretti, Qingfeng Zhu, Wei Fu, Jeffrey Meyer, Hao Wang, Robert A. Anders, and Nilofer S. Azad from Johns Hopkins University School of Medicine, researchers investigated neoadjuvant chemoradiotherapy (nCRT)-induced changes in CD8+ tumor infiltrating lymphocyte, PD-L1 and mucin expression in rectal cancer patients. “The synergistic effects of CRT and PD-1/PD-L1 immunotherapy has been supported by several retrospective analyses in different cancer types, including esophageal cancer, bladder cancer, and lung cancer also support[ed] [14, 21, 22]. However, the role of nCRT to interact synergistically with immune checkpoint inhibitor treatment to improve tumor control in rectal cancer remains uncertain.” Full press release - https://www.oncotarget.com/news/pr/oncotarget-chemoradiation-induced-alteration-of-programmed-death-ligand-cd-tumor-infiltrating-lymphocytes-and-mucin-expression-in-rectal-cancer/ DOI: https://doi.org/10.18632/oncotarget.28255 Correspondence to: Marina Baretti – Email: mbarett1@jh.edu Keywords: programmed death ligand 1, tumor-infiltrating lymphocytes, immune checkpoints, colorectal cancer, neoadjuvant chemoradiotherapy About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media: Twitter – https://twitter.com/Oncotarget Facebook – https://www.facebook.com/Oncotarget YouTube – www.youtube.com/c/OncotargetYouTube Instagram – https://www.instagram.com/oncotargetjrnl/ LinkedIn – https://www.linkedin.com/company/oncotarget/ Pinterest – https://www.pinterest.com/oncotarget/ LabTube – https://www.labtube.tv/channel/MTY5OA SoundCloud – https://soundcloud.com/oncotarget For media inquiries, please contact: media@impactjournals.com
July 15, 2022 RJ podcast: Who Rescues Who? Lung Cancer Hypofractionation and Proton Therapy. The latest podcast by Sue Yom, MD, Editor-in-Chief of the International Journal of Radiation Oncology, Biology, Physics addresses the status of hypofractionation in radiation therapy for locoregonally advanced lung cancer. Articles discussed include Hoppe et al.'s article "Chemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: A Proton Collaborative Group Phase 2 Trial", Contreras et al.'s article "Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non Small Cell Lung Cancer", and Brownstein and Salama's editorial, "Moderately Hypofractionated Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: A New Way Forward for Dose Escalation?" which is available in the July 15, 2022 issue.
Rick Greene, MD, and Nicole Lopez, MD, discuss a watch and wait approach to treating rectal cancer with complete clinical response after neoadjuvant therapy, which reduces overall costs and increases effectiveness compared with radical resection. Dr. Lopez is author of, “Cost Effectiveness of Watch and Wait Versus Resection in Rectal Cancer Patients with Complete Clinical Response to Neoadjuvant Chemoradiation.” Dr. Lopez is Director of the UC San Diego National Accreditation Program for Rectal Cancer (NAPRC), and is an Associate Professor of Surgery at UC San Diego Health, San Diego, CA.
Commentary by Dr. Bonnie Ky
This podcast highlights original research published in the October 2021 issue of Otolaryngology–Head and Neck Surgery, the official journal of the American Academy of Otolaryngology—Head and Neck Surgery (AAO-HNS) Foundation. Pathologic extranodal extension (ENE) is an important adverse feature for human papillomavirus (HPV)–negative head and neck squamous cell carcinoma (HNSCC), but the prognostic significance of microscopic ENE (ENEmi) and role of adjuvant concurrent chemoradiation (CRT) for ENEmi remain unclear. This study evaluates (1) the prognostic significance of ENEmi in HPV-negative HNSCC and (2) whether adjuvant CRT is associated with improved overall survival (OS) for these patients. In conclusion, for patients with HPV-negative HNSCC, pN+ with ENEmi is associated with worse OS than pN+ without ENE. However, for patients with ENEmi, concurrent CRT is not associated with improved OS relative to RT. The optimal adjuvant paradigm for ENEmi requires additional investigation. Click here to read the full article.
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
Listen to a soundcast of the February 22nd 2021 FDA approval of Libtayo (cemiplimab-rwlc) for first-line treatment of patients with advanced NSCLC (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Simone Marnitz-Schulze and Dr. Christhardt Köhler to discuss the outcomes of UTERUS-11 Trial. Drs. Marnitz-Schulze and Köhler are authors of “Surgical versus Clinical Staging prior to primary Chemoradiation in Patients with Cervical Cancer FIGO Stages IIB-IVA: Oncologic Results of a Prospective Randomized International Multicentre (Uterus-11) Intergroup Study,” which is the Lead Article of the December 2020 issue of the International Journal of Gynecological Cancer. Highlights: -Surgical staging prior to chemoradiation in locally advanced cervical cancer is safe, feasible, does not delay chemoradiation -Lead to an upstaging in 33% of the patients -Resulted into a statistically significant improvement of DFS in FIGO stage IIB patients -Resulted into a trend for improved OS and DFS for all subgroups -Because of high rates of distant metastases, systemic treatment has to be intensified
Host: Jennifer Caudle, DO Guest: Kristin Higgins, MD Concurrent chemoradiation therapy is the recommended treatment for unresectable Stage III NSCLC patients. Dr. Jennifer Caudle is joined by Dr. Kristin Higgins to discuss advances in radiation that optimize the treatment plan and her best practices to help patients receive a full course of curative-intent treatment. US-32345 Last Updated 12/19
Host: Jennifer Caudle, DO Guest: Kristin Higgins, MD Concurrent chemoradiation therapy is the recommended treatment for unresectable Stage III NSCLC patients. Dr. Jennifer Caudle is joined by Dr. Kristin Higgins to discuss advances in radiation that optimize the treatment plan and her best practices to help patients receive a full course of curative-intent treatment. US-32345 Last Updated 12/19
Host: Jennifer Caudle, DO Guest: Kristin Higgins, MD Concurrent chemoradiation therapy is the recommended treatment for unresectable Stage III NSCLC patients. Dr. Jennifer Caudle is joined by Dr. Kristin Higgins to discuss advances in radiation that optimize the treatment plan and her best practices to help patients receive a full course of curative-intent treatment. US-32345 Last Updated 12/19
Pablo Kelly is a long term survivor of a glioblastoma multiforme brain tumour. Here we discuss how and why he decided to attempt to manage his disease with the aid of metabolic therapies.
Dr. Rick Greene and Dr. Basem Azab discuss the relationship of the interval between neoadjuvant chemoradiation-to-surgery in the treatment of esophageal cancer, and associated pathological complete response rate and overall survival rate. Dr. Azab is author of the Annals of Surgical Oncology article “Impact of Chemoradiation-to-Surgery Interval on Pathological Complete Response and Short- and Long-Term Overall Survival in Esophageal Cancer Patients.” Dr. Azab is a surgical oncology specialist at Sentara Healthcare, Newport News, VA. His clinical expertise includes but is not limited to Esophageal Cancer, Endocrine Tumors, Gastrointestinal Oncology, Hepatobiliary Tumors.
GreenRanger has a packed episode of The Duel Assessment Podcast. This episode goes over the entire miniBOX, Lords of Shining, new cards from Duelist Chronicles, the new Extra Deck +, as well as the latest esports from Duel Links Meta. The question of the week discusses whether the current Ranked Duels is worth play at […]
Prof Corry talks to ecancertv at IAOO 2015 about chemoradiation in head and neck cancer and the difference in survival outcomes from big centres compared to small ones. She also notes the need for investigator-driven trials which look into aspects of treatment that are not a pharmaceutical company's top priority.
Prof Özsahin talks to ecancertv at IAOO 2015 about his work looking at chemoradiotherapy versus radiotherapy in head and neck cancer.
Dr Ridge talks to ecancertv at IAOO 2015 about the role of induction chemotherapy and concurrent chemoradiation in treating unresectable head and neck cancer. He also discusses his therapy and treatment recommendations for doctors.
Prof Perry talks to ecancertv at ASCO 2016 about a phase III randomised controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma.
Dr. Nasser Hanna, Indiana University Health, discusses the possible role of immunotherapy in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, discusses the possible role of immunotherapy in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, discusses the possible role of immunotherapy in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, lists chemo regiments appropriate for use with radiation in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, lists chemo regiments appropriate for use with radiation in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, lists chemo regiments appropriate for use with radiation in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, considers the use of induction or consolidation chemotherapy for unresectable stage III NSCLC.
Dr. Nasser Hanna, Indiana University Health, considers the use of induction or consolidation chemotherapy for unresectable stage III NSCLC.
Dr. Nasser Hanna, Indiana University Health, considers the use of induction or consolidation chemotherapy for unresectable stage III NSCLC.
Dr. Nasser Hanna, Indiana University Health, discusses the development of chemoradiation as a standard of care for unresectable stage III NSCLC.
Dr. Nasser Hanna, Indiana University Health, discusses the development of chemoradiation as a standard of care for unresectable stage III NSCLC.
Dr. Nasser Hanna, Indiana University Health, discusses the development of chemoradiation as a standard of care for unresectable stage III NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.
Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.
Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.
Interview with Roger Stupp, MD, author of Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial
Dr Hong talks to ecancertv about one of the nursing sessions held at ASTRO 2015 that looked at the care of patients receiving chemoradiation. In the interview he outlines that the aims of the session were to provide an overview of the data and rationale for why certain chemoradiation strategies were developed and explain why chemotherapy and radiotherapy may be used concurrently or sequentially. Another focus was to look at toxicity and the management of side effects commonly seen with chemoradiation.
Dr. West reviews basic principles of treating locally advanced lung cancer, including the need to treat both local disease and possible distant disease, and the need to balance efficacy with toxicity.
Dr. West reviews basic principles of treating locally advanced lung cancer, including the need to treat both local disease and possible distant disease, and the need to balance efficacy with toxicity.
Dr. West reviews basic principles of treating locally advanced lung cancer, including the need to treat both local disease and possible distant disease, and the need to balance efficacy with toxicity.
This trial supports the use of neoadjuvant capecitabine monotherapy as a potentially more convenient radiosensitizer that does not sacrifice surgical and pathologic outcomes in rectal cancer. However, further study is needed.
Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduction to key issues addressed in trials from ASCO 2013.
Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduction to key issues addressed in trials from ASCO 2013.
Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduction to key issues addressed in trials from ASCO 2013.
Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduction to key issues addressed in trials from ASCO 2013.
Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduction to key issues addressed in trials from ASCO 2013.
Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduction to key issues addressed in trials from ASCO 2013.
This podcast provides commentary and observations on the long term results summary of RTOG 91-11 in which concurrent chemoradiation was shown to provide superior outcome over induction chemotherapy or radiation alone to achieve larynx preservation and locoregional tumor control.
Dr. H. Jack West, medical oncologist from Swedish Cancer Institute in Seattle, WA, reviews the general principles of treating locally advanced non-small cell lung cancer (NSCLC).
Dr. Julie K. Heimbach discusses her manuscript "Efficacy of Neoadjuvant Chemoradiation, Followed by Liver Transplantation, for Perihilar Cholangiocarcinoma at 12 US Centers."
In this study, the implications of long term follow up of the German Rectal Study on clinical practice and future trial design will be discussed.
This podcast will explore the feasibility of a nonoperative "wait and see" approach based on strict selection criteria in patients with locally advanced rectal cancer who achieve a complete clinical response after chemoradiation.
Case-based discussion with multiple lung cancer experts on the controversial question of whether to recommend consolidation chemotherapy after concurrent chemotherapy and radiation for locally advanced NSCLC.
Case-based discussion with multiple lung cancer experts on the controversial question of whether to recommend consolidation chemotherapy after concurrent chemotherapy and radiation for locally advanced NSCLC.
Case-based discussion with multiple lung cancer experts on the optimal treatment of a patient with multi-station N2 node-positive squamous cell NSCLC, including whether surgery should be pursued.
Case-based discussion with multiple lung cancer experts on the optimal treatment of a patient with multi-station N2 node-positive squamous cell NSCLC, including whether surgery should be pursued.
The addition of oxaliplatin to fluorouracil-based neoadjvuant chemoradiation for locally advanced rectal cancer significantly increases toxicity but does not improve the pathologic complete response rate.
Case discussion with Drs. George Blumenschein of MD Anderson and Walter Curran of Emory University, covering management approaches for a stage IIIB locally advanced NSCLC with ambiguous imaging results after chemo and radiation were completed.
Case discussion with Drs. George Blumenschein of MD Anderson and Walter Curran of Emory University, covering management approaches for a stage IIIB locally advanced NSCLC with ambiguous imaging results after chemo and radiation were completed.
Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, discussing options for administering multimodality therapy for stage III NSCLC in patients who are elderly or have a marginal performance status.
Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, discussing options for administering multimodality therapy for stage III NSCLC in patients who are elderly or have a marginal performance status.
This slide presentation by Dr. Ramiswamy Govindan, medical oncologist at Washington University in St. Louis, offers a broad perspective on the history of treating cancer with chemotherapy, our current treatment approaches, and a preview of emerging technologies that are poised to become a more individualized way of treating cancer.
This slide presentation by Dr. Ramiswamy Govindan, medical oncologist at Washington University in St. Louis, offers a broad perspective on the history of treating cancer with chemotherapy, our current treatment approaches, and a preview of emerging technologies that are poised to become a more individualized way of treating cancer.
This slide presentation by Dr. Shirish Gadgeel, medical oncologist at Wayne State University, discusses the considerations and evidence about whether locally advanced (Stage III) NSCLC should be managed surgically or with chemo/radiation alone.
This slide presentation by Dr. Shirish Gadgeel, medical oncologist at Wayne State University, discusses the considerations and evidence about whether locally advanced (Stage III) NSCLC should be managed surgically or with chemo/radiation alone.
This slide presentation is part of a lecture by medical oncologist and lung cancer expert Dr. Jack West, in which he covers the optimal treatment strategies for locally advanced (stage III), unresectable NSCLC.
This slide presentation by medical oncologist and lung cancer expert Dr. Jack West covers the most common management strategies for stage IIIA N2 node-positive NSCLC, with a particular focus on a comparison of preoperative treatment followed by surgery vs. chemo and radiation without surgery.